+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
ID06285279

Evaluating BCMACD19 Dual Targeted CAR-T Cell Therapy for Adults with Relapsed or Refractory Autoimmune Kidney Diseases

Led by Nanjing University School of Medicine · Updated on 2026-07-06

24

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effects of BCMACD19 dual targeted CAR-T cell therapy FKC289 in adults with relapsed or refractory autoimmune kidney diseases including lupus nephritis, ANCA-associated vasculitis, membranous nephropathy, and IgG4-related diseases. This phase 1, open-label, dose-escalation study plans to enroll 6 to 12 participants using a Bayesian Optimal Interval design with four dose groups ranging from 0.1 to 3.0 x 106 CAR T cellskg. Participants undergo leukapheresis to collect cells for manufacturing the CAR-T therapy. Before infusion, they receive lymphodepletion with fludarabine and cyclophosphamide over three days. After a one-day rest, participants receive a single intravenous infusion of the assigned dose of BCMACD19 dual targeted CAR-T cells. Bridging therapy is permitted between cell collection and lymphodepletion. Following infusion, participants are followed for at least two years. During the study, participants are monitored for dose-limiting toxicities within 28 days and adverse events within 24 weeks after infusion. Researchers also measure renal response within 6 months and track duration of response, progression-free survival, and overall survival over 2 years. Assessments include clinical evaluations and laboratory tests to ensure safety and evaluate treatment effects over the study period.

CONDITIONS

Brief Title

The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases

Research Team

X

Xianghua Huang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here